000078 Shenzhen Neptunus Bioengineering
- 2.35
- +0.13+5.86%
Shenzhen Neptunus Bioengineering News
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Business And Shares Still Trailing The Industry
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment opportunity when you consider close to half the companies
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan
Shenzhen Neptunus Bioengineering (SHE:000078), through its subsidiary Shandong Neptune Galaxy Pharmaceutical, will build the first phase of a smart logistics park for 298 million yuan, according to th
Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term Shenzhen Neptunus Bioengin
Haiwang Biotech (000078.SZ): It has now built a diversified, multi-level pharmaceutical product structure
Gelonghui, Feb. 5 | Haiwang Biotech (000078.SZ) said on the investor interactive platform that the company's pharmaceutical industry sector is mainly engaged in drug R&D, production and sales, with subsidiaries Haiwangfu Pharmaceutical, Jinxiang Traditional Chinese Medicine and Haiwang Zhongxin Pharmaceutical as the main platforms. The company has now built a diversified and multi-level pharmaceutical product structure. Haiwang Pharmaceutical's main business is R&D, production and sales of large infusion products, Western medicine preparations, etc.; Jinxiang Traditional Chinese Medicine is a medium-sized traditional Chinese medicine manufacturer and sales enterprise in Fujian Province, responsible for R&D, production and sales of proprietary Chinese medicines; Haiwang Zhongxin Pharmaceutical is a company integrating R&D, production and sales of pharmaceutical products
Shenzhen Neptunus Bioengineering (SZSE:000078) Has A Somewhat Strained Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Why Investors Shouldn't Be Surprised By Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Low P/S
With a price-to-sales (or "P/S") ratio of 0.2x Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) may be sending very bullish signals at the moment, given that almost half of all the Healthcare
Neptune Biotech (000078.SZ): NEP018 of NEP018 of NEP018 from NEP018 was approved by the US FDA to enter human clinical trials
Gelonghui, December 29丨Haiwang Biotech (000078.SZ) announced that the company's wholly-owned subsidiary Shenzhen Haiwang Pharmaceutical Technology Research Institute Co., Ltd. (“Haiwang Pharmaceutical Research Institute”) recently received a written notice from the US Food and Drug Administration to approve NEP018, a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and with independent intellectual property rights, to carry out human clinical trials of phase I drugs in the US. NEP018 is a novel tumor vascular inhibitor independently developed by Haiwang Pharmaceutical Research Institute and has independent intellectual property rights. Comprehensive non-clinical study showed that NEP018 was effective against VEGF
Neptune Biotech (000078.SZ): Currently, the average account period for the company's accounts receivable is about six months
Gelonghui, December 13|Haiwang Biotech (000078.SZ) said at an investor relations event that the company is indeed low in terms of profit margins compared to several companies with state-owned backgrounds in the same industry. The main reason is that the company has high financing costs as a private enterprise, and the company's customers are mainly public medical institutions. Currently, the average account period for the company's accounts receivable is about six months, and the number of inventory turnover days is more than one month. After deducting the upstream accounts payable period, the company's actual operating capital consumption is more than four months. This has also led to a decrease in the company's capital turnover efficiency, which further affects the company's profit margin. In terms of operating income,
Shenzhen Neptunus Bioengineering (SZSE:000078) Adds CN¥413m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 20%
Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) shareholders should be happy to see the share price up 11% in the last month. But that cannot eclipse the less-than-impressive returns over
Neptune Biotech (000078.SZ): Cooperates with companies such as Novartis and Pfizer to act as a sales agent for related pharmaceuticals
Gelonghui November 7: Some investors asked Haiwang Biotech (000078.SZ) on the investor interactive platform, “How is the company's strategic cooperation with major multinational pharmaceutical companies progressing?” The company replied that it has cooperated with companies such as Novartis and Pfizer to act as agents for the sale of related pharmaceuticals.
Is Shenzhen Neptunus Bioengineering (SZSE:000078) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Neptune Biotech (000078.SZ) announced first-half results and net profit of 87.68 million yuan, down 22.92% year-on-year
Neptune Biotech (000078.SZ) disclosed the 2023 semi-annual report. The company achieved operating income of 1 during the reporting period...
Shareholders in Shenzhen Neptunus Bioengineering (SZSE:000078) Have Lost 31%, as Stock Drops 5.8% This Past Week
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Shenzhen Neptunus Bioengineering to Set Up 150 Million Yuan Medical Equipment Unit
Shenzhen Neptunus Bioengineering (SHE:000078) plans to establish a medical equipment unit with a registered capital of 150 million yuan, according to a filing on Wednesday. The Chinese pharmaceutical
Investors in Shenzhen Neptunus Bioengineering (SZSE:000078) From Five Years Ago Are Still Down 42%, Even After 5.3% Gain This Past Week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing a
Shenzhen Neptunus Bioengineering Warns of Loss in 2022
04:42 AM EST, 02/01/2023 (MT Newswires) -- Shenzhen Neptunus Bioengineering (SHA:603259) expects to swing to an attributable loss of between 800 million yuan and 960 million yuan, or between 0.2908 yu
Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) Delivered A Weaker ROE Than Its Industry
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to
Shenzhen Neptunus Bioengineering's (SZSE:000078) Five-year Decline in Earnings Translates Into Losses for Shareholders
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term
Can Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) Improve Its Returns?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to e
Shenzhen Neptunus Bioengineering (SZSE:000078) sheds CN¥825m, company earnings and investor returns have been trending downwards for past five years
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But in any portfolio, there will be mixed results between individual s
Analysis
Price Target
No Data
